Group 1 - The company, Wei Jun Biotechnology (00660), expects a net loss of no more than HKD 6 million for the six months ending December 31, 2025, which represents a significant reduction compared to a net loss of approximately HKD 13.1 million for the six months ending December 31, 2024 [1] - The substantial decrease in loss is primarily attributed to an increase in revenue and a reduction in financial costs during the reporting period [1]

原标题：兼具电子显微镜与荧光显微镜双重优势新成像技术能同步观测细胞精细结构 团队解释道，他们开发的新技术不发射光线，而是发射电子束。他们开发了一种特殊探针，可附着在目 标蛋白上。当电子束激发探针时，其会发出可见光，此过程称为"阴极发光"。于是，同一束电子束便能 提供两组关键信息：探针发出的彩色信号，以及电子散射形成的精细结构图像。该技术已在哺乳动物细 胞及生物组织（如受真菌侵染的果蝇）中验证有效。 不过，现行方法仅能生成二维平面图像，团队计划将其拓展至三维领域。下一步的目标是将该技术应用 于冷冻电子显微镜，通过快速冷冻技术保持细胞自然状态，并从多角度成像，最终构建出细胞的3D模 型。（刘霞） 原标题：兼具电子显微镜与荧光显微镜双重优势新成像技术能同步观测细胞精细结构 来源：科技日报 受真菌感染果蝇的多色电子显微镜图像。图中可见真菌的细胞核（绿色）、线粒体（紫色）以及果蝇表 面的精细结构。 图片来源：物理学家组织网 这一突破解决了生物成像领域长期存在的两难困境：以往科学家要么能看清细胞的精细结构，要么能追 踪特定分子，却难以两者兼得。新技术的问世，为解析细胞信号传导到分子簇组织等各类生命过程打开 了新窗口，也让 ...

受真菌感染果蝇的多色电子显微镜图像。图中可见真菌的细胞核（绿色）、线粒体（紫色）以及果蝇表 面的精细结构。图片来源：物理学家组织网 科技日报北京2月24日电 （记者刘霞）美国哈佛大学科学家研制出一种新型成像技术。这是一种多色显 微镜技术，巧妙融合了电子显微镜与荧光显微镜的双重优势，使研究人员能在纳米级分辨率下，同步观 测细胞的精细结构与特定蛋白质位置。相关成果已于2月21日至25日在美国旧金山召开的第70届生物物 理学会年会上发布。 传统荧光显微镜通过将发光标签附着于目标蛋白，利用可见光激发标签发光来定位分子。这一技术虽擅 长"定点"，但其分辨率约250—300纳米，无法清晰分辨单个蛋白质，更难以观察细胞的整体骨架。反 之，电子显微镜虽能以纳米级精度精确描绘细胞结构，却难以识别特定的分子标记。 此前，科学家曾尝试将两种图像拍摄后叠加，但对于脑组织等大尺寸样本，图像的精确对齐极难实现。 哈佛团队的解决方案简洁而优雅：弃用双重成像，改用单束电子束实现"一石二鸟"。 团队解释道，他们开发的新技术不发射光线，而是发射电子束。他们开发了一种特殊探针，可附着在目 标蛋白上。当电子束激发探针时，其会发出可见光，此过程称为" ...

Core Insights - Researchers from the University of Pennsylvania and Harvard have developed an electronic implant system that can monitor and influence the maturation of human islet cells, providing a key technological platform for creating functional human pancreas and new approaches for cell-based diabetes therapies [1][2]. Group 1: Technology Development - The team embedded a thin conductive mesh structure within lab-grown pancreatic tissue, allowing the electronic device to closely interact with biological tissue. This system can record electrical signals produced by islet cells and apply precise electrical stimulation to influence their development [1][2]. - The implantable device is described as "bionic" or "cyber-organ," combining electronic systems with living tissue to create a controllable biological system [1]. Group 2: Research Findings - The researchers implanted a stretchable electronic mesh within developing three-dimensional pancreatic organoids, which is thinner than a human hair. This structure was placed between cell layers, allowing cells to aggregate and form islets. The device enabled the recording of electrical activity from individual islet cells for up to two months, observing their maturation process [2]. - By introducing a 24-hour electrical activity cycle similar to the human circadian rhythm, the cells were able to maintain this rhythmic activity autonomously after several days of stimulation, leading to improved hormone secretion at appropriate times [2]. Group 3: Future Applications - The technology may have two potential applications: first, to "train" lab-cultured islet cells through electrical stimulation before transplanting them into patients; second, to retain the electronic mesh structure post-transplant for continuous monitoring and moderate stimulation of cells to prevent functional decline under stress or disease [2].

Group 1 - The A-share IPO market is showing clear signs of recovery, with the number of projects under review increasing by over 146% compared to the same period last year, while the number of terminated reviews has decreased by over 85% [1] - New quality productivity-related sectors have become the core focus for the year, indicating a shift in investment strategies [1] - The maturity of quantitative big data technology allows for precise capture of the true intentions of funds, moving beyond mere speculation based on market trends [1] Group 2 - The article emphasizes the importance of recognizing the consensus among different types of funds, as this often leads to above-average performance of related stocks [1] - Quantitative tools can help identify signals of active trading behavior, such as "speculative capital rushing to buy," which indicates a consensus among funds [5][9] - The article illustrates that even before a stock shows significant price movement, quantitative data can reveal active trading behaviors, suggesting potential value [9][14] Group 3 - The article discusses the commonality of fund logic across different industries, asserting that similar trading traces are left when two types of funds reach consensus, regardless of industry attributes [12] - It highlights that the use of quantitative tools can provide clarity on trading behaviors, helping investors avoid being misled by short-term price fluctuations [7][16] - The current warming of the IPO market and focus on new quality productivity sectors present opportunities for investors to leverage quantitative tools for better decision-making [16]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 3.1% [1] - The total value of China’s innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The current valuation of the pharmaceutical sector is considered attractive, with a recommendation to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1] - The ETF tracking the CSI Biotechnology Theme Index, managed by E Fund, has seen a decline of 0.3% [4] - The ETF tracking the CSI Pharmaceutical and Health Index, also managed by E Fund, has similarly decreased by 0.3% [4]

Core Viewpoint - Charoen Pokphand International (03839) reported a significant increase in revenue and profit for the fiscal year ending December 31, 2025, primarily driven by substantial growth in its biotechnology business [1] Financial Performance - The company achieved revenue of approximately $536 million, representing a year-on-year growth of 74.14% [1] - Shareholders' profit attributable to the company was $32.055 million, marking a year-on-year increase of 187.03% [1] - Basic earnings per share were reported at 12.65 cents [1] Business Growth - The notable rise in profit is attributed mainly to the remarkable growth in the company's biotechnology segment [1]

Core Viewpoint - Charoen Pokphand International (03839) reported a significant increase in revenue and profit for the fiscal year ending December 31, 2025, primarily driven by strong growth in its biotechnology business [1] Financial Performance - The company achieved revenue of approximately $536 million, representing a year-on-year growth of 74.14% [1] - Shareholders' profit attributable to the company was $32.055 million, marking a year-on-year increase of 187.03% [1] - Basic earnings per share were reported at 12.65 cents [1]

Group 1 - The core viewpoint of the article is that Zhengda Enterprise International (03839.HK) reported a significant revenue increase of 74.1% to $535.9 million for the fiscal year ending December 31, 2025, compared to $307.7 million in 2024, primarily driven by its biotechnology business [1] - The substantial revenue growth is attributed to the successful implementation of key strategies focused on developing large customer sales, with a notable contribution from the growth of immunobiological products [1] - The overall gross profit margin decreased from 15.9% in 2024 to 14.4% in 2025, indicating a shift in profitability despite revenue growth [1] Group 2 - The company's profit attributable to shareholders for 2025 was $32.1 million, up from $11.2 million in 2024, reflecting significant growth in the biotechnology segment [1]

Group 1 - The core point of the article is that China Biotechnology Services has completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met [1] - The convertible bonds were issued on February 20, 2026, according to the terms and conditions of the subscription agreement [1] - Prior to the issuance of the new convertible bonds, there remains an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HKD 1.20 per share [1]